Lack of Evidence and Consequential Harm Caused by Mydriatic Regimens Used in Retinopathy of Prematurity Screening

Lisa Kremer1, Roland Broadbent2, David Reith2, Natalie J Medlicott1
School of Pharmacy1, and Department of Women’s and Children’s Health2, University of Otago.

Introduction

- Very preterm infants require mydriatic eye drops in preparation for retinopathy of prematurity (ROP) screening.
- In New Zealand and Australia, approx. 3,500 premature infants/year are screened for ROP.
- 66% of infants screened don’t have ROP.

Systematic review

- To systematically review literature for efficacy and safety of mydriatic regimens used in ROP screening.
- Survey
  - To determine the variation of NICU mydriatic regimens within New Zealand and Australia.
  - To estimate the frequency of adverse drug events after mydriatic administration.

Methods

Systematic review

- Two review authors independently carried out the literature search.
- Publications that evaluated efficacy and safety of mydriatic regimens, in premature infants, were included in the review.
- MEDLINE via Ovid, PubMed, Web of Science, Cochrane Library and Cochrane Neonatal Review Group, Google Scholar, and Scopus databases were searched.

Survey

- A Survey Monkey questionnaire was emailed to selected nursing staff at Neonatal Intensive Care Units (NICU).
- Staff were identified in the Directory of NICU within Australia and New Zealand 2017 register.
- The target survey population were staff who administer the mydriatic medicines for ROP screening.

Aims

- To determine the variation of NICU mydriatic regimens within New Zealand and Australia.
- To estimate the frequency of adverse drug events after mydriatic administration.

Discussion

- Results from pilot studies suggest that there is very little benefit in administering larger doses when smaller doses are effective.
  - A robust data set is lacking.
  - Neonatal nurses associate mydriatics with significant harm, including NEC and death.
  - Side effects are seen if systemic or transdermal absorption occurs.
  - Consequential harm caused by mydriatic medicines used in ROP screening should not be occurring.

Systematic review

- 10 papers were identified (all small sample size).
- Nine studies compared various combinations of phenylephrine and cyclopentolate and/or tropicamide.
- Irrespective of the combination of medications, pupil dilation results were above 5mm.
- 2014 Vicente et al results show a non-significant difference in pupil dilation in all regimens (Figure 1).
- 5 studies noted an increase in blood pressure.
- 1 study noted an increase in feed intolerance.

Survey

- 46 neonatal nurses from Australia (n=30) and New Zealand (n=16) participated in the survey.
- 11 different mydriatic regimens were identified (Tables 1).
- Regimens F and G were the most common regimens (n=18).
- Phenylephrine dosing ranged from 70 µg to 1950 µg (28 fold difference).
- Cyclopentolate dosing ranged from 14 µg to 260 µg (18 fold difference).
- Tropicamide dosing ranged from 260 µg to 780 µg (3 fold difference).
- Very often skin blanching apnoea, tachycardia, feed intolerance occurred (Figure 2).
- Sometimes hypertension, tachycardia, apnoea, feed intolerance, skin blanching occurred (Figure 2).
- Rarely NEC, HTN, tachypnoea, feed intolerance, seizure, skin blanching occurred.
- Nursing staff reported seeing additional adverse effects following mydriatic administration; bradycardia, abdominal distension and death.

Results

- Figure 1. Vicente et al 1 Mean pupil size for phenylephrine 1% and cyclopentolate 0.2%
- Table 1. Reported mydriatic regimens in New Zealand and Australia.

Conclusions

- A sufficiently powered data set is required to a) establish low dose efficacy of mydriatic medicines, b) incidence of adverse drug effects, with a focus on the most vulnerable infants.

Acknowledgements

Contributing NICU staff from around NZ and Australia. Rewa Peni Professional Photographer. PhD Scholarship; University of Otago. Conference Scholarship; Dunedin School of Medicine.

References


Further information

Email: Lisa.Kremer@otago.ac.nz